Biopharmaceutical firm SuppreMol has raised €16m ($20.6m) in series D funding in a round backed by MIG AG, Santo Holding and BioMedPartners AG as co-lead investors.

Also joining the round were FCP Biotech Holding and research group the Max Planck Society.

The round was made up out of two closes with the same investors. The first close of €6.5m was back in September 2012, while the latest close two days ago was for €9.5m. In total, the firm has raised…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?